公开(公告)号：US20240091216A1

公开(公告)日：2024-03-21

申请号：US18503992

申请日：2023-11-07

Applicant: AeroRx Therapeutics LLC

Inventor： John CHAN ,  Keith Try UNG ,  Mei-Chang KUO ,  John Nigel Pritchard

IPC: A61K31/4704 ,  A61K9/00 ,  A61K9/08 ,  A61K9/12 ,  A61K31/40 ,  A61K31/5386 ,  A61K31/58 ,  A61K47/10 ,  A61K47/26 ,  A61K47/69 ,  A61P11/00

CPC classification number: A61K31/4704 ,  A61K9/0078 ,  A61K9/08 ,  A61K9/12 ,  A61K31/40 ,  A61K31/5386 ,  A61K31/58 ,  A61K47/10 ,  A61K47/26 ,  A61K47/6951 ,  A61P11/00

Abstract: Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

公开(公告)号：US11903949B2

公开(公告)日：2024-02-20

申请号：US16539894

申请日：2019-08-13

Applicant: OSSIFI THERAPEUTICS LLC

Inventor： Debra Ellies ,  F. Scott Kimball ,  Robert N. Young

IPC: C07D471/04 ,  C07D498/08 ,  C07D491/048 ,  A61K31/5377 ,  A61K39/395 ,  A61K31/444 ,  A61K31/496 ,  A61K35/32 ,  A61K31/5386 ,  A61P19/10 ,  A61K31/55

CPC classification number: A61K31/5377 ,  A61K31/444 ,  A61K31/496 ,  A61K31/5386 ,  A61K31/55 ,  A61K35/32 ,  A61K39/3955 ,  A61P19/10 ,  C07D471/04 ,  C07D491/048 ,  C07D498/08

Abstract: In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.

公开(公告)号：US11844793B2

公开(公告)日：2023-12-19

申请号：US17449412

申请日：2021-09-29

Applicant: AeroRx Therapeutics LLC

Inventor： John Chan ,  Keith Try Ung ,  Mei-Chang Kuo ,  John Nigel Pritchard

IPC: A61K31/4704 ,  A61K31/5386 ,  A61K31/40 ,  A61K9/00 ,  A61K47/69 ,  A61K47/26 ,  A61K31/58 ,  A61K9/08 ,  A61K9/12 ,  A61K47/10 ,  A61P11/00

CPC classification number: A61K31/4704 ,  A61K9/0078 ,  A61K9/08 ,  A61K9/12 ,  A61K31/40 ,  A61K31/5386 ,  A61K31/58 ,  A61K47/10 ,  A61K47/26 ,  A61K47/6951 ,  A61P11/00

Abstract: Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

公开(公告)号：US11814378B2

公开(公告)日：2023-11-14

申请号：US16738444

申请日：2020-01-09

Applicant: AC Immune SA

Inventor： Sreenivasachary Nampally ,  Emanuele Gabellieri ,  Jerome Molette

IPC: C07D471/04 ,  A61P25/28 ,  C07D471/14 ,  A61K31/4375 ,  A61K31/5386 ,  A61K31/473 ,  A61K31/27 ,  A61K31/445 ,  A61K31/55 ,  A61K31/455 ,  A61K31/13 ,  A61K31/5377 ,  A61K31/437 ,  C07D519/00 ,  A61K31/4709 ,  A61K31/444 ,  C07D491/147

CPC classification number: C07D471/04 ,  A61K31/13 ,  A61K31/27 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/445 ,  A61K31/455 ,  A61K31/473 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61P25/28 ,  C07D471/14 ,  C07D491/147 ,  C07D519/00

Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

公开(公告)号：US20230321033A1

公开(公告)日：2023-10-12

申请号：US18019486

申请日：2021-08-05

Applicant: ENYO PHARMA

Inventor： RAPHAËL DARTEIL ,  STÉPHANIE LE CORRE ,  ERIC MELDRUM ,  FABIOLA TERZI ,  JACKY VONDERSCHER

IPC: A61K31/381 ,  A61K31/5377 ,  A61K31/5386 ,  A61P13/12

CPC classification number: A61K31/381 ,  A61K31/5377 ,  A61K31/5386 ,  A61P13/12

Abstract: The present invention relates to a method for treating renal fibrosis.

公开(公告)号：US11739100B2

公开(公告)日：2023-08-29

申请号：US16282265

申请日：2019-02-21

Applicant: SANOFI

Inventor： Youssef El-Ahmad ,  Bruno Filoche-Romme ,  Jean-Philippe Letallec ,  Gilbert Marciniak ,  Baptiste Ronan ,  Bertrand Vivet ,  Maurice Brollo

IPC: C07D519/00 ,  C07D233/46 ,  C07D239/14 ,  C07D239/70 ,  C07D471/04 ,  C07D487/04 ,  C07D295/04 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K45/06

CPC classification number: C07D519/00 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K45/06 ,  C07D233/46 ,  C07D239/14 ,  C07D239/70 ,  C07D295/04 ,  C07D471/04 ,  C07D487/04

Abstract: The invention relates to the novel products of formula (I):




with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH2)m—Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; —SO2—Rb; —CO—Re; m=1 or 2; Ra=aryl, heteroaryl, —CO-cycloalkyl, —CO-heterocycloalkyl, —CO—Rb, —C(Rb)═N—ORc, —CO2Rd, —CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is





and the isomer of configuration R,R





these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.

公开(公告)号：US20230143502A1

公开(公告)日：2023-05-11

申请号：US17960625

申请日：2022-10-05

Applicant: Teon Therapeutics, Inc.

Inventor： Elfatih Elzein ,  Jiwen Liu

IPC: A61K31/5377 ,  C07D471/04 ,  C07D519/00 ,  A61K39/395 ,  A61K31/4375 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/5386 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/444

CPC classification number: A61K31/5377 ,  C07D471/04 ,  C07D519/00 ,  A61K39/3955 ,  A61K31/4375 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/5386 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2054 ,  A61K9/4825 ,  A61K31/444

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

公开(公告)号：US11642350B2

公开(公告)日：2023-05-09

申请号：US16495350

申请日：2018-03-22

Applicant: Singapore Health Services PTE LTD ,  Santen Pharmaceutical Co., Ltd.

Inventor： Tiang Hwee Donald Tan ,  Roger Wilmer Beuerman ,  Seang-Mei Saw ,  Aradhana Upadhyay ,  Masatomo Kato ,  Takaaki Inaba

IPC: A61K31/5386 ,  A61P27/10 ,  A61K9/00

CPC classification number: A61K31/5386 ,  A61K9/0048 ,  A61P27/10

Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

公开(公告)号：US11642342B2

公开(公告)日：2023-05-09

申请号：US17140664

申请日：2021-01-04

Applicant: Accutar Biotechnology

Inventor： Jie Fan ,  Yimin Qian ,  Wei He

IPC: A61K31/496 ,  A61K31/519 ,  A61K31/506 ,  A61P35/00 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/444 ,  A61K31/551 ,  A61K31/5386 ,  A61K31/4985 ,  A61K31/4439

CPC classification number: A61K31/496 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5386 ,  A61K31/551 ,  A61P35/00

Abstract: Provided herein are pharmaceutical combinations, compositions, and methods of using a compound with estrogen receptor (ER) degradation activity, such as a compound of formula (I) or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate thereof, wherein R1, Y, R22, R33, R2, p, X3, X4, and Z are defined herein and a cyclin-dependent kinase (CDK) inhibitor.

公开(公告)号：US20230082993A1

公开(公告)日：2023-03-16

申请号：US17568991

申请日：2022-01-05

Applicant: GENOSCO Inc.

Inventor： Wongil LEE ,  William G. DEVINE ,  R. Bruce DIEBOLD ,  So Young HWANG ,  Yunggeun CHOI ,  Yan LIU ,  Sang-Ae SEUNG ,  Miyong YONG ,  Sewon KIM ,  Jaekyoo LEE ,  Jong Sung KOH

IPC: A61K31/4725 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D513/04 ,  C07D471/04 ,  C07D498/08 ,  C07D403/04 ,  C07D403/14 ,  A61K31/496 ,  A61K31/4375 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/517 ,  A61K31/675 ,  C07F9/6558

Abstract: The present invention relates to novel substituted bicyclic derivatives that can inhibit Rho-kinases and/or Rho-kinase mediated phosphorylation of myosin light chain phosphates, compositions comprising the derivatives, methods for preparing the derivatives, and methods for using the derivatives and/or compositions.